Research programme - natural killer cell therapeutics - Fate Therapeutics

Drug Profile

Research programme - natural killer cell therapeutics - Fate Therapeutics

Alternative Names: FT 500; FT 516; FT 819; FT500i; FT516i; hnCD16-iNK; iNK Cells; NcHaCD16-NKs

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fate Therapeutics; University of Minnesota
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 May 2018 Fate Therapeutics in-licenses intellectual property covering new chimeric antigen receptor (CAR) constructs, off-the-shelf CAR-T cells, including the use of CRISPR and other technologies for development of FT 819 from Memorial Sloan Kettering Cancer Center
  • 16 May 2018 Fate Therapeutics owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control
  • 10 May 2018 Fate Therapeutics intends to file an IND with the US FDA for FT 500 for Solid tumours (Late-stage disease, Combination therapy) in the second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top